In its January 2025 meeting, CHMP recommended 8 drugs for approval, including 4 innovative, 3 biosimilars, and 1 generic drugs. The committee has also recommended extensions of indication for 8 drugs.
What is covered in the Full Insight:
Introduction
CHMP Recommendations
Key Drug Approvals and Developments
Biosimilars and Generics Overview
Regulatory Challenges and Withdrawn Applications
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.